Contact Us
Drug Search Results
More Filters [+]

Epoprostenol

Alternative Names: epoprostenol, prostacyclin, prostaglandin i2, flolan, veletri
Latest Update: 2024-10-09
Latest Update Note: News Article

Product Description

Epoprostenol is a synthetic analogue of the naturally occurring eicosanoid prostacyclin (prostaglandin I2 or PGI2), which is the main metabolite of arachidonic acid (Sourced from: https://err.ersjournals.com/content/26/143/160055)

Mechanisms of Action: PGI2 Agonist,PA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Chile | Colombia | Czech | Denmark | Estonia | France | Germany | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Japan | Luxembourg | Malta | Netherlands | New Zealand | Norway | Poland | Portugal | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States

Approved Indications: Hypertension | Hypertension, Pulmonary | Hypertension | Hypertension, Pulmonary

Known Adverse Events: Dizziness | Headache | Pain Unspecified | Musculoskeletal Pain | Bradycardia | Tachycardia | Hypotension | Abdominal Pain | Chest Pain | Chronic Pain | Dyspnea | Diarrhea | Flushing

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Epoprostenol

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Hypertension, Pulmonary

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CR109201

P1

Completed

Hypertension, Pulmonary

2023-12-05

21%

Recent News Events

Date

Type

Title

10/09/2024

News Article

 DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

09/24/2024

News Article

 United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

09/04/2024

News Article

 WINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension

08/26/2024

News Article

 Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions